Trial Profile
An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric Patients With Spinal Muscular Atrophy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms Jewelfish
- Sponsors Roche
- 22 Jun 2023 This trial has been completed in Germany.
- 22 Jun 2023 This trial has been completed in Germany.
- 06 May 2023 Results assessing the in vivo FMO3 ontogeny by mechanistic population pharmacokinetic (Mech-PPK) modelling of risdiplam using the data collected healthy individuals or SMA patients who participated in five clinical trials (NCT02633709, NCT03032172, NCT02908685, NCT02913482, NCT03988907, published in the Clinical Pharmacokinetics.